SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001654954-18-009975
Filing Date
2018-09-07
Accepted
2018-09-07 17:00:54
Documents
3
Period of Report
2018-09-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT gtbp_8k.htm 8-K 29257
2 FORM OF 10% SENIOR CONVERTIBLE DEBENTURE gtbp_ex41.htm EX-4.1 175702
3 SECURITIES PURCHASE AGREEMENT BY AND AMONG THE COMPANY AND THE PURCHASERS, DATED gtbp_ex101.htm EX-10.1 298535
  Complete submission text file 0001654954-18-009975.txt   504986
Mailing Address 1825 K STREET SUITE 510 WASHINGTON, D.C. DC 33602
Business Address 1825 K STREET SUITE 510 WASHINGTON, D.C. DC 33602 (800) 304-9888
GT Biopharma, Inc. (Filer) CIK: 0000109657 (see all company filings)

IRS No.: 941620407 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-08092 | Film No.: 181060707
SIC: 2834 Pharmaceutical Preparations